Loading company…
Teitur Trophics develops circular peptide treatments for neurodegenerative disorders.
Teitur Trophics researches circular peptides for conditions including Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. Its work focuses on receptors involved in neural function, and its lead candidate is TT-P34. Founded in 2020, the company is based in Aarhus, Denmark. In March 2023, it raised EUR 28 million in Series A funding co-led by Sound Bioventures and Sunstone Life Science Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in